MedPath

Study of inhaler use in asthma and COPD

Not Applicable
Completed
Conditions
Asthma and chronic obstructive pulmonary disease
Respiratory
Registration Number
ISRCTN10844309
Lead Sponsor
Fundação Portuguesa do Pulmão (FPP, Portuguese Lung Foundation)
Brief Summary

2021 results in https://doi.org/10.1016/j.rmed.2021.106507 (added 17/06/2021)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
201
Inclusion Criteria

1. Aged = 18 years old at trial enrolment
2. Self-reported asthma or COPD diagnosis
3. Chronic or first user of any of the following inhaler devices : Breezhaler; Ellipta; Spiromax; Turbohaler; pMDI; Respimat

Exclusion Criteria

1. Pregnant women
2. Individuals with any cognitive impairment
3. Motor limitations that jeopardize the performance of the technique or any other condition that not allow them to understand the study objectives or the completion of the questionnaires
4. Patients who do not give their informed consent

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of asthma, COPD and all patients (irrespective of their diagnosis asthma or COPD) who achieve 100% in the assessment of inhaler technique score at 6 months
Secondary Outcome Measures
NameTimeMethod
<br> Assessed at baseline and 6 months:<br> 1. Difference between baseline and 6-month follow-up inhaler technique score<br> 2. COPD disease-specific HRQoL measured by COPD Assessment Test™ (CAT)<br> 3. Disease control status measured by the Asthma Control Test™ (ACT) for Asthma patients and the Modified Medical Research Council Dyspnea Questionnaire (mMRC) for COPD patients<br> 4. Number of Adverse Drug Events (ADEs) collected by patient questionnaire<br> 5. Number of disease exacerbations collected by patient questionnaire<br> 6. Health care resource utilization and costs collected by patient questionnaire<br><br> Additional analysis will be conducted to explore and potentially identify factors affecting the control of the diseases.<br>
© Copyright 2025. All Rights Reserved by MedPath